Key result
Transfer factor therapy is linked to nephropathy in ~16% of patients with Wiskott-Aldrich syndrome.
Why the study?
Renal failure occurs in the Wiskott-Aldrich syndrome more frequently than generally recognized and the effect of transfer factor therapy on renal disease is unclear.
Does transfer factor therapy precipitate or accelerate renal disease in patients with Wiskott-Aldrich syndrome?
Population
32 patients with Wiskott-Aldrich syndrome
Comparison
Patients receiving transfer factor therapy vs those not receiving transfer factor therapy
Design
Observational study
Follow-up
Up to 5½ years
Authors
Loading...
May warrant renal monitoring with transfer factor in Wiskott-Aldrich syndrome; hypothesis-generating observation that leaves open causality and needs prospective confirmation.
Observational (n=32)
Does transfer factor therapy precipitate or accelerate renal disease in patients with Wiskott-Aldrich syndrome?
Renal failure is a significant complication in Wiskott-Aldrich syndrome that may be exacerbated by transfer factor therapy.
S̄pitler et al. (1980) conducted an observational in Wiskott-Aldrich syndrome (n=32). Transfer factor (TF) therapy was evaluated on Nephropathy or decreased renal function. Transfer factor therapy may precipitate or accelerate renal disease in patients with Wiskott-Aldrich syndrome, with nephropathy detected in 5 of 32 treated patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: